Microplastics and Nanomaterials: Understanding Emerging Contaminants in Environmental Testing

🎤Matthew BolinoHow do the hidden carbohydrate structures on your favorite protein powders shape the gut microbiome? &nbsp;In this episode of Concentrating on Chromatography, Matthew Bolino, M.S., from the University of Nevada, Reno, breaks down his latest research on N‑glycans from common dietary proteins (whey, egg white, soy, and pea) and how their structural diversity influences microbial fermentation and short‑chain fatty acid production.Bolino explains what N‑glycans are, why they behave like fiber in the gut, and how his team isolates and characterizes them using ethanol washes, enzymatic release (PNGase F and gut‑derived endoglycosidases), and advanced MALDI‑TOF and HILIC‑QTOF workflows. &nbsp;He also discusses his 2025 work comparing synthetic versus bovine whey N‑glycomes and mapping N‑glycan profiles across dietary protein sources, revealing how glycan architecture can reshape community diversity in in vitro fecal fermentations.Geared toward undergraduate and early‑career analytical chemists, this conversation dives into practical mass spec trade‑offs (MALDI vs QTOF vs LC/GC), real‑world troubleshooting in glycomics labs, and how microbiome‑targeted therapeutics and “symbiotic” designs may emerge from pairing specific microbes with preferred glycan structures. &nbsp;Bolino closes with career advice on building biomolecular analysis skills, understanding instrumentation fundamentals, and entering the rapidly growing field of glycomics and microbiome research.<h3>Video Transcription</h3><h4>Introduction</h4>Glycomics has emerged as a rapidly developing field within biomolecular science, expanding our understanding of post-translational modifications beyond well-known processes such as phosphorylation. Among these modifications, protein glycosylation—the covalent attachment of carbohydrate structures to proteins—plays a critical role in biological function, molecular recognition, and cellular communication.This discussion focuses on N-glycans, a class of structurally complex carbohydrates linked to proteins, and their occurrence in common dietary protein sources such as whey, egg white, soy, and pea protein. Particular emphasis is placed on their structural diversity, analytical workflows, and emerging relevance in gut microbiome research.<h4>Fundamentals of N-Glycans</h4>N-glycans are oligosaccharide structures covalently attached to proteins via nitrogen atoms, typically at asparagine residues. They represent one of the two major classes of protein glycosylation, alongside O-glycans.These glycans are characterized by:<ul><li>High structural diversity, arising from variations in monosaccharide composition and linkage patterns</li><li>Large size, typically comprising 7–15 monosaccharide units</li><li>Complex branching architectures, leading to a vast number of possible configurations</li></ul>Common monosaccharide components include:<ul><li>Mannose</li><li>Galactose</li><li>N-acetylglucosamine</li><li>N-acetylgalactosamine</li><li>Sialic acids</li></ul>Unlike free carbohydrates present in foods (e.g., glucose, lactose), N-glycans are protein-bound, which significantly influences their biological behavior.<h4>Biological Function and Dietary Relevance</h4>N-glycans play multiple roles in biological systems, including:<ul><li>Modulation of protein stability</li><li>Regulation of protein trafficking and localization</li><li>Facilitation of cell–cell communication and immune recognition</li></ul>They are particularly abundant on membrane and surface proteins, where they contribute to molecular signaling processes.From a dietary perspective, N-glycans exhibit unique behavior. Due to their size and protein-bound nature, they are not readily digested in the upper gastrointestinal tract. Instead, they can reach the colon, where they may function analogously to dietary fiber, interacting with the gut microbiota.<h4>Research Motivation</h4>The investigation of N-glycans in dietary proteins was initially driven by interest in protein nutrition and supplementation, particularly in the context of muscle growth and protein quality. However, this focus expanded upon recognition of the importance of glycosylation in biological systems.The field of glycomics offers:<ul><li>Extensive structural variability, enabling diverse biological functions</li><li>Relevance in disease mechanisms, including cancer, where glycosylation patterns can influence immune evasion</li><li>Opportunities to explore diet–microbiome interactions</li></ul>This combination of nutritional, biochemical, and biomedical relevance makes N-glycan research particularly compelling.<h4>Experimental Workflow for N-Glycan Analysis</h4>The analysis of N-glycans requires a multi-step workflow due to their covalent attachment to proteins.<h5>1. Protein Purification</h5>Dietary protein samples often contain:<ul><li>Free sugars</li><li>Lipids</li><li>Other matrix components</li></ul>To isolate glycoproteins:<ul><li>Cold ethanol precipitation is used to remove free carbohydrates</li><li>Multiple washing steps ensure removal of residual sugars</li><li>A phenol–sulfuric acid assay is applied to confirm the absence of free sugars</li></ul><h5>2. Enzymatic Release of N-Glycans</h5>N-glycans are enzymatically cleaved from proteins using:<ul><li>PNGase F (Peptide-N-Glycosidase F)</li></ul>This enzyme:<ul><li>Specifically cleaves the glycan from the protein backbone</li><li>Preserves the intact glycan structure</li></ul>Alternative approaches using gut-derived enzymes are being explored to improve accessibility and yield.<h5>3. Glycan Purification and Labeling</h5>Following release:<ul><li>Glycans are purified from the protein matrix</li><li>Chemical labeling is performed (e.g., 2-AA or procainamide tagging)</li></ul>Labeling enhances:<ul><li>Detection sensitivity</li><li>Chromatographic behavior</li></ul><h5>4. Analytical Techniques</h5>Two primary analytical platforms are employed:<ul><li>MALDI-TOF MS<ul><li>High sensitivity</li><li>Broad structural coverage</li></ul></li><li>HILIC-LC-MS<ul><li>Improved reproducibility</li><li>Enhanced chromatographic separation</li></ul></li></ul>These approaches provide semi-quantitative data, where signal intensity reflects relative abundance rather than absolute concentration.<h4>Analytical Challenges</h4>Several challenges are associated with N-glycan analysis:<h5>Low Abundance</h5><ul><li>Dietary proteins typically contain only 1–2% glycan content by weight</li><li>This limits yield and complicates downstream applications</li></ul><h5>Sample Preparation Complexity</h5><ul><li>Extensive purification is required to eliminate free sugars</li><li>Contamination risks must be carefully managed</li></ul><h5>Instrumentation Trade-Offs</h5><ul><li>Different analytical platforms offer complementary advantages</li><li>No single technique provides complete structural and quantitative information</li></ul><h4>Differences Between Plant and Animal N-Glycans</h4>Comparative analysis reveals distinct differences in glycan composition:<h5>Plant-Derived Proteins (e.g., soy, pea)</h5><ul><li>Predominantly high-mannose structures</li><li>Lower monosaccharide diversity</li><li>Simpler glycan architectures</li></ul><h5>Animal-Derived Proteins (e.g., whey, egg white)</h5><ul><li>Greater structural complexity</li><li>Inclusion of diverse monosaccharides (e.g., sialic acids)</li><li>More elaborate branching patterns</li></ul>These differences have important implications for biological function and microbial interactions.<h4>Implications for Gut Microbiome Research</h4>N-glycans represent a potential class of prebiotic substrates that can influence gut microbiota composition and activity.Key findings suggest:<ul><li>Structural diversity of glycans affects microbial utilization patterns</li><li>More complex glycans may promote greater microbiome diversity</li><li>Specific glycan structures may selectively stimulate beneficial microbes</li></ul>This has led to growing interest in:<ul><li>Synbiotic strategies, combining microbes with preferred substrates</li><li>Tailored dietary interventions to enhance metabolic outputs, such as short-chain fatty acids</li></ul><h4>Methodological Considerations</h4>A critical insight from this work is the importance of understanding analytical trade-offs:<ul><li>MALDI-TOF MS provides broader detection of glycan structures</li><li>LC-MS approaches offer greater reproducibility</li></ul>No single technique is universally optimal; instead, method selection should be guided by the specific research question.<h4>Conclusion</h4>N-glycans in dietary proteins represent a complex and biologically significant class of biomolecules with implications spanning nutrition, microbiology, and disease research. Advances in analytical methodologies continue to improve our ability to characterize these structures, despite challenges related to low abundance and structural diversity.A deeper understanding of N-glycan composition and function may enable the development of targeted nutritional strategies and microbiome-based therapeutics, highlighting the growing importance of glycomics in modern life sciences.<blockquote>This text has been automatically transcribed from a video presentation using AI technology. It may contain inaccuracies and is not guaranteed to be 100% correct.</blockquote><blockquote><h4>Concentrating on Chromatography Podcast</h4>Dive into the frontiers of chromatography, mass spectrometry, and sample preparation with host David Oliva. Each episode features candid conversations with leading researchers, industry innovators, and passionate scientists who are shaping the future of analytical chemistry. From decoding PFAS detection challenges to exploring the latest in AI-assisted liquid chromatography, this show uncovers practical workflows, sustainability breakthroughs, and the real-world impact of separation science. Whether you’re a chromatographer, lab professional, or researcher you'll discover inspiring content!You can find Concentrating on Chromatography Podcast in podcast apps:<ul><li><a target="_blank" rel="noopener noreferrer" href="https://open.spotify.com/show/1wZg67rCjoGju4yhqxI3tL">Spotify</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://podcasts.apple.com/tz/podcast/concentrating-on-chromatography/id1788429185">Apple podcast</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://podscan.fm/podcasts/concentrating-on-chromatography">podscan</a></li></ul>and on <a target="_blank" rel="noopener noreferrer" href="https://www.youtube.com/@ChromatographyTalk/videos">YouTube channel</a></blockquote>

N‑Glycans, Whey Protein, and the Gut Microbiome: Mass Spec Insights with Matthew Bolino

<div><div><div>Our immune system is incredibly powerful: among other things, it can recognize and destroy cancer cells. But tumors can be just as effective at avoiding detection – they build “invisibility shields” to protect themselves from attack.</div></div><div>One breakthrough in cancer therapy has been immune checkpoint inhibitors (ICIs), drugs that reactivate immune T cells and help them fight tumors again. However, only about 20–50% of patients respond well to this treatment. Researchers are therefore seeking alternative therapeutic strategies. A small and well-known molecule called adenosine plays a key role in these efforts.When tumor cells are stressed or dying, they release ATP, which is normally a signal that something is wrong in the tissue. But in the tumor microenvironment, ATP gets rapidly broken down by two enzymes, CD39 and CD73. Released adenosine acts like a chemical “calm-down” signal, binds to immune cells (T cells, NK cells, and others), and tells them to slow down, reducing their ability to kill cancer cells. Targeting CD73 therefore represents a promising strategy for developing new cancer treatments.</div><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/UOCHB_Nove_latky_mohou_podporit_imunitni_system_v_boji_s_rakovinou_88c5e82cd5.jpeg" alt="IOCB Prague: Development of potent inhibitors to boost the immune system's ability to fight cancer" srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_UOCHB_Nove_latky_mohou_podporit_imunitni_system_v_boji_s_rakovinou_88c5e82cd5.jpeg 245w," sizes="100vw" width="661" height="363">At IOCB Prague, interdisciplinary teams led by Jan Řezáč, Jan Konvalinka, and Michal Hocek used a newly developed high-throughput screening method to test over 5,000 compounds, identifying two ribonucleoside derivatives as promising CD73 inhibitors.The scientists then improved the compounds’ activity by carefully modifying the ribonucleoside scaffold with bulky (het)aryl groups. Further optimization improved the pharmacokinetic properties of these compounds, yielding inhibitors with low clearance, long half-life, high solubility, and strong selectivity over related enzymes such as CD39.In cellular experiments, the compounds reduced adenosine production in cancer cells, restored T cell activation, and showed no toxicity toward human fibroblasts. The most active compound showed a single-digit picomolar inhibition constant (Ki).These findings establish a strong foundation for further in vivo efficacy and combination studies, which will explore the therapeutic potential of this novel inhibitor class.<blockquote><h4>The Original article</h4><h4><a target="_blank" rel="noopener noreferrer" href="https://pubs.acs.org/doi/10.1021/acsptsci.5c00707">Potent Competitive Inhibitors of Ecto-5′-nucleotidase (CD73) based on 6-(Het)aryl-7-deazapurine Ribonucleoside 5′-O-Bisphosphonates</a></h4>Ugnė Šinkevičiu̅tė, Magdalena Šímová, Radek Staník, Lenka Poštová Slavětínská, Kristýna Blažková, Pavel Šácha, Martin Lepšík, Jan Řezáč, Jan Konvalinka, Tereza Ormsby, Michal Tichý, Michal HocekACS Pharmacol. Transl. Sci. 2026, 9, 1, 191–213<a target="_blank" rel="noopener noreferrer" href="https://pubs.acs.org/doi/10.1021/acsptsci.5c00707">https://pubs.acs.org/doi/10.1021/acsptsci.5c00707</a><h6>licensed under <a target="_blank" rel="noopener noreferrer" href="https://creativecommons.org/licenses/by/4.0/">CC-BY 4.0</a></h6></blockquote><h4>Abstract</h4>CD73 generates immunosuppressive adenosine in the tumor microenvironment and is a promising target for cancer immunotherapy. We have designed and systematically studied diverse 2-substituted 7-deazapurine ribonucleoside 5′-O-bisphosphonates bearing a variety of (het)aryl groups at position 6 and discovered their highly potent and selective CD73 inhibition activity. The most active compounds (with single-digit picomolar Ki) contained bicyclic (het)aryl groups at position 6 in combination with chlorine at position 2. Further optimization of pharmacokinetic properties identified inhibitors with low clearance, long half-life, high solubility, and excellent selectivity over CD39 and NTPDase3. They effectively suppressed adenosine formation in MDA-MB-231 cells, rescued CD8+ T cell activation, and were nontoxic to human fibroblasts. Overall, their profile compares favorably with AB680, a CD73 inhibitor currently in phase I/II clinical trials.</div>

Development of potent inhibitors to boost the immune system's ability to fight cancer

Article

Video

Scientists

Environment

Scientific article

Interview

Science and research

The Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences (IOCB Prague) is a leading scientific institution in the Czech Republic, recognized internationally. Its primary mission is basic research in the fields of chemical biology and medicinal chemistry, organic and material oriented chemistry, chemistry of natural compounds, biochemistry and molecular biology, physical chemistry, theoretical chemistry, and analytical chemistry. 

Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences

Organomation, founded in 1959, designs and manufactures high-quality nitrogen evaporators and extraction systems. Known for innovation and durability, their lab instruments are used globally for efficient sample preparation with strong customer support.

Organomation

Agilent manual crimper for 20 mm caps, 5040-4669 (New)

Manual crimper for 20 mm caps, designed to provide consistent and reliable vial sealing for routine laboratory use.

Agilent Captiva Premium Syringe Filter, 5190-5111 (New)

Agilent Captiva Premium syringe filter with regenerated cellulose (RC) membrane, 25 mm diameter and 0.45 µm pore size. Designed for sample filtration before LC/HPLC analysis with aqueous and organic solvents.

Agilent SF, PTFE, 25 mm, 0.45 µm syringe filters, 5191-5915 (New)

Agilent PTFE syringe filters (25 mm, 0.45 µm, 5191-5915) deliver reliable particle removal, high chemical resistance, and clean sample prep for chromatography and lab workflows.

Agilent SF, PTFE-HI, 13 mm, 0.45 µm, hydrophilic syringe filters, 5191-5917 (New)

Agilent PTFE-HI syringe filters (13 mm, 0.45 µm, 5191-5917) provide clean aqueous and organic samples with hydrophilic PTFE, high chemical resistance, and reliable filtration.

Agilent SF, PVDF, 25 mm, 0.45 µm syringe filters, 5191-5927 (New)

Agilent PVDF syringe filters (25 mm, 0.45 µm, 5191-5927) offer low protein binding, broad chemical compatibility, and efficient particle removal for chromatography and lab workflows.

Agilent SF, PTFE-HI, 25 mm, 0.45 µm, hydrophilic (2 x 250 pcs), 5191-5919 (New)

Agilent PTFE-HI syringe filters (25 mm, 0.45 µm, 5191-5919) in bulk pack (2 × 250 pcs) provide hydrophilic, chemically resistant filtration for aqueous and organic samples.

Agilent Captiva Syringe Filter Nylon. 25 mm diameter, 0.45 µm pore size, 1000/pk, 5190-5272 (New)

Agilent Captiva Nylon syringe filters (25 mm, 0.45 µm, 1000/pk, 5190-5272) offer universal lab use with solvent-compatible Nylon 66 membranes in durable polypropylene housings.

Marketplace products from category Sample preparation focused on Consumables from Agilent Technologies - page 1

Related content

Development of potent inhibitors to boost the immune system's ability to fight cancer

N‑Glycans, Whey Protein, and the Gut Microbiome: Mass Spec Insights with Matthew Bolino

Microplastics and Nanomaterials: Understanding Emerging Contaminants in Environmental Testing